Autoimmune Pulmonary Alveolar Proteinosis Completed Phase 1 Trials for Sargramostim (DB00020)

Back to Autoimmune Pulmonary Alveolar Proteinosis

Also known as: Pulmonary Alveolar Proteinosis, Autoimmune / Autoimmune pulmonary alveolar proteinosis (disorder) / Alveolar proteinosis / Pulmonary Alveolar Proteinosis / Pulmonary alveolar proteinosis (disorder)

IndicationStatusPhase
DBCOND0075037 (Autoimmune Pulmonary Alveolar Proteinosis)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02840708
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudyTreatment
NCT03006146
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar ProteinosisBasic Science